<- Go Home
Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Market Cap
CAD 96.7M
Volume
60.4K
Cash and Equivalents
CAD 23.4M
EBITDA
-CAD 26.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-CAD 17.7M
Profit Margin
N/A
52 Week High
CAD 1.32
52 Week Low
CAD 0.38
Dividend
N/A
Price / Book Value
4.68
Price / Earnings
-3.36
Price / Tangible Book Value
4.68
Enterprise Value
CAD 73.3M
Enterprise Value / EBITDA
-2.80
Operating Income
-CAD 26.2M
Return on Equity
85.23%
Return on Assets
-45.01
Cash and Short Term Investments
CAD 23.4M
Debt
N/A
Equity
CAD 20.6M
Revenue
N/A
Unlevered FCF
-CAD 12.9M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium